Replicel Life Sciences Inc
XTSX:RP
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.01
0.1
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CAD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Replicel Life Sciences Inc
Replicel Life Sciences Inc
Income from Continuing Operations
Replicel Life Sciences Inc
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Replicel Life Sciences Inc
XTSX:RP
|
Income from Continuing Operations
-CA$69.3k
|
CAGR 3-Years
69%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
|
|
Abcellera Biologics Inc
NASDAQ:ABCL
|
Income from Continuing Operations
-$146.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Arch Biopartners Inc
XTSX:ARCH
|
Income from Continuing Operations
-CA$6.1m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-35%
|
|
|
Innovotech Inc
XTSX:IOT
|
Income from Continuing Operations
-CA$364.5k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-116%
|
CAGR 10-Years
7%
|
|
Replicel Life Sciences Inc
Glance View
RepliCel Life Sciences, Inc. is a regenerative medicine company, which engages in the development of autologous cell therapies that treat functional cellular deficits including chronic tendon injuries, androgenetic alopeci, and skin aging. The company is headquartered in Vancouver, British Columbia and currently employs 1 full-time employees. The company went IPO on 2012-09-29. The company is focused on developing autologous cell therapies that treat functional cellular deficits including chronic tendon injuries, androgenetic alopecia, and skin aging. Its product pipeline includes RCT-01 for Tendon Repair, RCS-01 for Skin Rejuvenation, RCH-01 Hair Growth and RCI-02 Dermal Injector Publication . RCT-01 is an autologous cell-based treatment utilizing non-bulbar dermal sheath cells isolated from the hair follicle for the treatment of chronic Achilles tendinopathy. RCS-01 is an autologous cell therapy being developed to rejuvenate aging or Ultraviolet (UV)-damaged skin. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCI-02 is a dermal injector designed to deliver a variety of injectable substances in and under the skin with a range of needle configurations.
See Also
What is Replicel Life Sciences Inc's Income from Continuing Operations?
Income from Continuing Operations
-69.3k
CAD
Based on the financial report for Sep 30, 2023, Replicel Life Sciences Inc's Income from Continuing Operations amounts to -69.3k CAD.
What is Replicel Life Sciences Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
51%
Over the last year, the Income from Continuing Operations growth was 98%. The average annual Income from Continuing Operations growth rates for Replicel Life Sciences Inc have been 69% over the past three years , 51% over the past five years .
You don't have any saved screeners yet
